PTX3 Is an Extrinsic Oncosuppressor Regulating Complement-Dependent Inflammation in Cancer  by Bonavita, Eduardo et al.
Article
PTX3 Is an Extrinsic Oncosuppressor Regulating
Complement-Dependent Inflammation in CancerGraphical AbstractHighlightsd PTX3 deficiency unleashes Complement-dependent tumor-
promoting inflammation
d Tumors developed in a PTX3-deficient context have higher
frequency of mutated Trp53
d PTX3 expression is epigenetically repressed in selected
human tumors
d Complement is an essential component of tumor-promoting
inflammationBonavita et al., 2015, Cell 160, 700–714
February 12, 2015 ª2015 Elsevier Inc.
http://dx.doi.org/10.1016/j.cell.2015.01.004Authors
Eduardo Bonavita, Stefania Gentile, ...,
Cecilia Garlanda, Alberto Mantovani
Correspondence
cecilia.garlanda@humanitasresearch.it
(C.G.),
alberto.mantovani@humanitasresearch.it
(A.M.)
In Brief
PTX3 deficiency triggers Complement-
dependent tumor-promoting
inflammation, with enhanced tumor
burden, macrophage infiltration, cytokine
production, angiogenesis, and genetic
instability, revealing the role of this innate
immunity mediator as an extrinsic
oncosuppressor.
ArticlePTX3 Is an Extrinsic Oncosuppressor Regulating
Complement-Dependent Inflammation in Cancer
Eduardo Bonavita,1 Stefania Gentile,1 Marcello Rubino,1 Virginia Maina,1 Roberto Papait,1,2 Paolo Kunderfranco,1
Carolina Greco,1 Francesca Feruglio,1 Martina Molgora,1 Ilaria Laface,1 Silvia Tartari,1 Andrea Doni,1 Fabio Pasqualini,1
Elisa Barbati,1 Gianluca Basso,1 Maria Rosaria Galdiero,1 Manuela Nebuloni,3 Massimo Roncalli,1
Piergiuseppe Colombo,1 Luigi Laghi,1 John D. Lambris,4 Se´bastien Jaillon,1 Cecilia Garlanda,1,*
and Alberto Mantovani1,5,*
1Humanitas Clinical and Research Center, Rozzano (Milan) 20089, Italy
2Institute of Genetics and Biomedical Research, National Research Council, Rozzano (Milan) 20089, Italy
3Pathology Unit, L. Sacco Department of Clinical Sciences, University of Milan, Milan 20157, Italy
4Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
5Humanitas University, Rozzano (Milan) 20089, Italy
*Correspondence: cecilia.garlanda@humanitasresearch.it (C.G.), alberto.mantovani@humanitasresearch.it (A.M.)
http://dx.doi.org/10.1016/j.cell.2015.01.004SUMMARY
PTX3 is an essential component of the humoral arm
of innate immunity, playing a nonredundant role in
resistance against selected microbes and in the
regulation of inflammation. PTX3 activates and regu-
lates the Complement cascade by interacting with
C1q and with Factor H. PTX3 deficiency was associ-
ated with increased susceptibility to mesenchymal
and epithelial carcinogenesis. Increased suscepti-
bility of Ptx3/ mice was associated with enhanced
macrophage infiltration, cytokine production, angio-
genesis, and Trp53 mutations. Correlative evidence,
gene-targeted mice, and pharmacological blocking
experiments indicated that PTX3 deficiency resulted
in amplification of Complement activation, CCL2 pro-
duction, and tumor-promoting macrophage recruit-
ment. PTX3 expression was epigenetically regulated
in selected human tumors (e.g., leiomyosarcomas
and colorectal cancer) by methylation of the pro-
moter region and of a putative enhancer. Thus,
PTX3, an effector molecule belonging to the humoral
arm of innate immunity, acts as an extrinsic oncosup-
pressor gene in mouse and man by regulating Com-
plement-dependent, macrophage-sustained, tumor-
promoting inflammation.
INTRODUCTION
Inflammatory cells and molecules are an essential component of
the tumor microenvironment (Coussens et al., 2013; Grivennikov
et al., 2010; Hanahan and Weinberg, 2011; Mantovani et al.,
2008). The connection between inflammation and cancer can
be viewed as consisting of two pathways. Selected inflammatory
conditions, the prototype of which is ulcerative colitis, increase
the risk of developing cancer (extrinsic pathway). On the other
hand genetic events that cause cancer orchestrate the construc-
tion of an inflammatorymicroenvironment even in tumors that are700 Cell 160, 700–714, February 12, 2015 ª2015 Elsevier Inc.epidemiologically unrelated to inflammation (Mantovani et al.,
2008). Genetic approaches have unequivocally proven the role
of cells andmediators (e.g., cytokines) of the innate and adaptive
immune system in sustaining tumor-promoting inflammation.
However, no dominant or suppressor oncogene encodes for
effector molecules of the humoral innate immune system.
The innate immune system includes a cellular and a humoral
arm (Garlanda et al., 2005). The humoral arm of innate immunity
is constituted of diverse molecules including Complement
components, collectins, ficolins, and pentraxins (Bottazzi et al.,
2010). The long pentraxin PTX3 is an essential component of
the humoral arm of innate immunity (Bottazzi et al., 2010; Gar-
landa et al., 2005). PTX3 acts as a functional ancestor of anti-
bodies: it interacts with selected microbial molecules (Jeannin
et al., 2005); it has opsonic activity via Fcg receptors (Moalli
et al., 2010); it activates and regulates the Complement cascade
by interacting with C1q and Factor H (Bottazzi et al., 1997; Deban
et al., 2008); and it regulates inflammation by interacting with
P-selectin via its glycosidic moiety (Deban et al., 2010). PTX3
plays a nonredundant role in resistance against selectedmicrobi-
al pathogens inmouse andman (Chiarini et al., 2010; Cunha et al.,
2014; Garlanda et al., 2002) and is a candidate therapeutic agent
against Aspergillus fumigatus and Pseudomonas aeruginosa.
In the context of an effort to translate this molecule to the clinic
as a novel candidate antimicrobial agent in cancer patients at
risk of infection (Cunha et al., 2014), it was important to assess
its role in carcinogenesis. We found that the humoral pattern
recognition molecule PTX3 acts as an oncosuppressor in mice
and humans by regulating Complement-dependent tumor-pro-
moting inflammation. This observation represents a missing
link in the connection between inflammation and cancer by
providing genetic evidence that an effector molecule of humoral
innate immunity can act as a cancer gene.RESULTS
PTX3 Deficiency Increases Susceptibility to Cancer
Development and Growth
In order to address the role of PTX3 in cancer-related inflamma-
tion (CRI) and tumor development, we analyzed the susceptibility
Figure 1. PTX3 Deficiency Increases Susceptibility to Carcinogenesis
(A and B) Incidence (A) and tumor volume (B) of 3-MCA-induced sarcoma in Ptx3/ and Ptx3+/+mice. In (B), the volume of each tumor is shown. One experiment
with 20 mice/group out of ten performed with similar results is shown.
(C) Effect of recombinant PTX3 (9 mg/day, s.c. by osmotic pump) administered from day 0 to 50,–100, or from 0–100 on tumor incidence.
(D and E) Incidence (D) and number of lesions (mean ± SEM) (E) of DMBA/TPA-induced skin papillomas in Ptx3/ and Ptx3+/+ mice. One experiment with ten
mice/group out of five performed with similar results is shown.
(F) Histological classification of lesions developed in Ptx3/ and Ptx3+/+ mice. **p < 0.01, Chi-square test. Two pooled experiments.
(A–E) *p < 0.05, **p < 0.01, ***p < 0.001 paired Student’s t test. See also Figure S1.of Ptx3/ mice in different models of mesenchymal or epithelial
carcinogenesis. As shown in Figure 1A, in the model of 3-Meth-
ylcholanthrene (3-MCA)-induced carcinogenesis, 80% Ptx3/
mice developed a sarcoma in comparison to 40% Ptx3+/+ mice
(p = 0.0002). Ptx3/ sarcomas grew faster than Ptx3+/+ tumors
and reached the endpoint (3 cm3) in 100–120 days, whereas
Ptx3+/+ tumors reached it in 170–220 days (Figure 1B). Treatment
with recombinant PTX3 subcutaneously (s.c.) throughout the
carcinogenesis process (days 0–100) completely rescued the
phenotype of Ptx3/ mice (Figure 1C). Early treatment (days
0–50) inhibited the early difference, with an increase in incidence
following interruption of treatment. A minor decrease in tumor
incidence was also observed when treatment was begun on
day 50 through day 100 (Figure 1C). The impact of PTX3 admin-
istration after day 50 may well reflect a role of Complement
(see below) in promotion of established transplanted tumors
(Markiewski et al., 2008). Treatment of Ptx3+/+ mice caused
some delay in tumor appearance but did not affect incidence
(Figure S1A available online).
We next addressed the relevance of PTX3 deficiency in a
model of 7,12-dimethylbenz [a] anthracene/terephthalic acid
(DMBA/TPA)-induced skin carcinogenesis. As shown in Figures
1D and 1E, both the incidence and the multiplicity of papillomas
were significantly increased in Ptx3/ mice in comparison to
Ptx3+/+ mice (p = 0.0004 and p = 0.0005, respectively). In addi-tion, the number of lesions evolving to skin carcinomas was
significantly higher in Ptx3/ mice (p = 0.009), suggesting a
more aggressive behavior of DMBA/TPA-induced skin lesion in
PTX3-deficient hosts (Figure 1F).
These data indicate that PTX3 is involved in controlling the
incidence and growth of tumors of both mesenchymal and
epithelial origin.
Production of PTX3 during Carcinogenesis
The following experiments, aimed at defining the underlying
cellular and molecular mechanisms, were focused on the 3-
MCA-induced carcinogenesis model. We first analyzed the pro-
duction of PTX3 during carcinogenesis. 3-MCA is a carcinogenic
compound acting as initiator and promoter, metabolized by the
liver. PTX3 levels were increased in serum (Figure 2A) and liver
(not shown) a few hours (8 and 24) after 3-MCA treatment,
whereas after 7 days they had returned to basal levels. At the in-
jection site, the levels of PTX3 were higher 24 hr after 3-MCA
treatment in comparison to vehicle and further increased at
day 7. PTX3 was originally cloned as an IL-1 inducible gene (Gar-
landa et al., 2005). It was therefore important to assess whether
IL-1 was upstream of PTX3 in 3-MCA carcinogenesis. Both sys-
temic and local PTX3 levels were significantly lower in Il1r1/
mice compared to wild-type mice, suggesting that in this model,
IL-1 is involved in PTX3 induction (Figure 2A). In establishedCell 160, 700–714, February 12, 2015 ª2015 Elsevier Inc. 701
Figure 2. Analysis of the Cellular Source of PTX3 and of Its Role in 3-MCA-Induced Carcinogenesis
(A) Systemic (upper panel) and local (lower panel) PTX3 production at different time points upon vehicle or 3-MCA injection in wild-type and Il-1r1/mice (mean ±
SEM). *p < 0.05, **p < 0.01, ***p < 0.001, unpaired Student’s t test.
(B) Immunohistochemical analysis of PTX3 expression in 3-MCA-induced sarcoma. Arrows show vessels (upper panel), infiltrating leukocytes (central panel), and
interstitial stroma (lower panel). Arrowheads show tumor cells (upper and central panels).
(C) Immunofluorescence analysis of PTX3 expression in blood vessels (CD31+ cells), macrophages (F4/80+ cells), and neutrophils (Ly6G+ cells). Scale bar
represents 150 mm.
(D) 3-MCA-induced sarcoma incidence in PTX3-chimeric mice (Donor/ Recipient). **p < 0.01, paired Student’s t test.
See also Figure S2.tumors (day 100), PTX3 immunostaining was associated with
vessels, macrophages, neutrophils, and interstitial stroma, but
not to tumor cells (Figures 2B and 2C). Accordingly, most sar-
coma cell lines isolated from Ptx3+/+ tumor-bearing mice did
not produce PTX3 in basal or inflammatory conditions (Fig-
ure S2C). PTX3 expression in cells of themonocyte-macrophage
lineage was confirmed by RT-PCR analysis, with highest levels in
MCHIIlow macrophages (see below) (Figure S2D). At early time
points (e.g., day 15), PTX3 expression was strongly induced in
F4/80+ cells (macrophages) in the skin and to a lesser extent in702 Cell 160, 700–714, February 12, 2015 ª2015 Elsevier Inc.liver, as well as in stromal cells (Figure S2A). In the latter cell
type, substantial coexpression of a marker of DNA damage
response (DDR), g-H2Ax, was observed only at early time points
to wane thereafter (Figure S2B). Collectively these results sug-
gest that infiltrating leukocytes and endothelial cells are a major
source of PTX3 and that silencing of PTX3 expression in tumor
cells occurs generally during progression.
Bone marrow chimeras were used to assess the relative
importance of hematopoietic and nonhematopoietic (including
tumor) cells as a source of PTX3 and in the protection against
Figure 3. PTX3 Deficiency Is Associated to Increased CRI
(A) Histological and immunohistochemical analysis of macrophage (CD68+) and neutrophil (Ly6G+) infiltration in Ptx3/ and Ptx3+/+ 3-MCA-injection site at
7 days.
(B) MPO levels in 3-MCA-injection site at 7 days (mean ± SEM). See also Table S1.
(C) Analysis of the leukocyte infiltrate in 3-MCA-sarcoma by FACS. Total leukocytes (CD45+), macrophages (F4/80+/CD11b+), monocytes (CD11b+/Ly6C+),
neutrophils (CD11b+/Ly6G+), and lymphocytes (CD3+) were analyzed (mean ± SEM).
(legend continued on next page)
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carcinogenesis. PTX3 tumor concentration in the two chimeric
groups (Ptx3+/+ mice receiving Ptx3/ bone marrow and
Ptx3/ mice receiving Ptx3+/+ bone marrow) were comparable
(2.15 ng/mg ± 0.8 ng/mg and 1.89 ng/mg ± 0.1 ng/mg) and sig-
nificantly lower than in Ptx3+/+ tumors (6.61 ng/mg ± 0.2 ng/mg,
p < 0.003), suggesting that both nonhematopoietic cells and he-
matopoietic cells produce PTX3 in tumors. PTX3 competence in
hematopoietic cells or in stromal cells was insufficient to recon-
stitute the full ‘‘protected’’ phenotype observed in Ptx3+/+ mice
or in reconstituted fully competent mice (Figure 2D). Thus,
PTX3 derived from both hematopoietic and nonhematopoietic
cells contributes to protection against carcinogenesis.
PTX3 Deficiency Is Associated with Increased
Cancer-Related Inflammation
PTX3 does not affect the proliferation of normal and transformed
cells (Figure S1B). It interacts with Fcg receptors (Lu et al., 2008;
Moalli et al., 2010) and has antibody-like properties (Bottazzi
et al., 2010) including the capacity to regulate inflammatory reac-
tions. Therefore, we focused on CRI in Ptx3/ mice. We first
evaluated leukocyte recruitment into the 3-MCA-injection site
at early time points in Ptx3+/+ and Ptx3/mice. As shown in Fig-
ure 3A, on day 7 after injection macrophages (CD68+ cells) and
neutrophils (Ly6G+ cells) recruited around 3-MCA-containing
corn oil droplets were more abundant in Ptx3/ compared to
Ptx3+/+ mice. In agreement, the MPO content (Figure 3B), as
well as the levels of CCL2 and CXCL2 (Table S1), were signifi-
cantly higher in homogenates of tissues collected from Ptx3/
mice, compared to Ptx3+/+ mice.
We next analyzed the leukocyte infiltrate of tumors collected at
their maximum volume (3 cm3) by flow cytometry. As shown in
Figure 3C, the percentage of macrophages (F4/80+/CD11b+
cells) and monocytes (Ly6Chigh/CD11b+ cells) in CD45+ cells
was higher in Ptx3/ compared to Ptx3+/+ mice, whereas the
percentage of neutrophils (Ly6Ghigh/CD11b+ cells) was signifi-
cantly lower. The percentage of T lymphocytes (CD3+ cells)
was comparable in the two groups. Similar results were obtained
when the analysis was performed at day 100 after 3-MCA-treat-
ment in tumors of different size in Ptx3/ and Ptx3+/+ mice (Fig-
ure S3A). Histological analysis confirmed increasedmacrophage
infiltration in Ptx3/ sarcomas and showed higher density of
CD31+ vessels (Figures 3D and 3E). Similar lymphocyte infiltra-
tion in the two groups was confirmed by histological analysis
(Figure 3F).
In addition, the concentrations of proinflammatory cytokines
TNFa, IL-1b and IL-6, CCL2, and the proangiogenic vascular
endothelial growth factor (VEGF) were significantly higher in
Ptx3/ tumor homogenates than in Ptx3+/+. IL-6 and VEGF
levels were significantly higher also at the systemic level in
Ptx3/ mice (Table S1). Treatment with recombinant PTX3
reduced macrophage infiltration and angiogenesis abolishing
the difference between the two genotypes (Figures 3G and S3B).(D–F) Analysis of macrophages (F4/80+ immunoreactive area, IRA), angiogenesi
histochemistry (each dot represents the average of ten fields, mean ± SEM).
(G) Analysis by FACS of themacrophage infiltrate (mean ±SEM) in 3-MCA-sarcom
0 to 100). *p < 0.05, **p < 0.01, unpaired Student’s t test.
See also Figure S3.
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Complement Activation
PTX3 has been shown to tune inflammatory responses bymodu-
lating P-selectin-dependent leukocyte recruitment and Comple-
ment activation (Deban et al., 2010; Inforzato et al., 2013). We
first addressed the role of PTX3-P-selectin interaction in leuko-
cyte recruitment and in tumor growth by evaluating sarcoma
incidence in P-selectin-deficient and in PTX3/P-selectin-dou-
ble-deficient mice. As shown in Figure S3C, we found that
PTX3 deficiency was associated to higher tumor incidence
regardless of P-selectin competence. Moreover, P-selectin defi-
ciency did not affect susceptibility to 3-MCA carcinogenesis.
Next, we analyzed Complement activation. Confocal micro-
scopy of the injection site revealed significantly higher C3 immu-
noreactivity in areas surrounding 3-MCA-containing oil droplets
in Ptx3/ mice, in comparison to Ptx3+/+ mice, where C3 depo-
sition was negligible (Figure 4A). In tumors, C3 deposition
occurred also in Ptx3+/+ lesions, but it was significantly lower
than in Ptx3/ sarcomas (Figure 4B, two pooled experiments).
An analysis of C3 deposition and PTX3 expression in each
Ptx3+/+ lesion was performed on samples from one experiment
and showed that C3 and PTX3 were significantly inversely corre-
lated (Pearson r = 0.65, p = 0.03). Treatment with recombinant
PTX3 reduced C3 immunoreactivity in Ptx3/ tumors to levels
observed in Ptx3+/+ tumors (Figure 4C).
In addition, a higher C5a concentration was measured in
Ptx3/ tumor homogenates compared to Ptx3+/+ ones (Fig-
ure 4D). In contrast, the immunoreactivity for C5b-9, which was
associated with necrotic tumor areas, did not differ in Ptx3/
and Ptx3+/+ tumors (Figure 4E). We next analyzed the immunore-
activity for Factor H and C4BP, because PTX3 interacts with
these two Complement-regulatory proteins without interfering
with their functional activity and facilitates their deposition on
damaged cells, amplifying their regulatory potential (Braunsch-
weig and Jo´zsi, 2011; Deban et al., 2008). As shown in Figure 4F,
the immunostaining for Factor H in tumors from Ptx3/ mice
was significantly lower than in Ptx3+/+ tumors. A correlation anal-
ysis showed that PTX3 expression and Factor H deposition were
significantly positively correlated (Pearson r = 0.71, p = 0.01). We
also observed lower C4BP deposition in Ptx3/ than in Ptx3+/+
tumors, but the difference did not reach statistical significance
(p = 0.07) (Figure S4A).
Role of Complement
In the effort to assess the pathogenic role of increased Comple-
ment activation associated to PTX3 deficiency, we evaluated the
susceptibility to 3-MCA of C3-deficient and PTX3/C3-double-
deficient mice. Carcinogenesis by 3-MCA and macrophage
recruitment in C3/ mice were significantly lower than in wild-
type animals (Figures 4G and 4H). In addition, C3 deficiency
reduced the susceptibility to 3-MCA of Ptx3/ mice to levels
comparable to that of Ptx3+/+ mice and double deficiency wass (CD31+ IRA), and lymphocytes (CD3+ cells) in 3-MCA-sarcoma by immuno-
a of Ptx3/ andPtx3+/+mice, after treatment with recombinant PTX3 (from day
associated to macrophage recruitment comparable to that of
C3/ mice. Finally, treatment with the C5a receptor antagonist
PMX53 reduced the susceptibility of Ptx3/ mice, reverting the
phenotype, without affecting the tumor growth in wild-type mice
(Figure 4I).
Factor H-deficient mice are depleted in circulating C3 and suf-
fer from spontaneous nephropathy (Pickering et al., 2002).
Therefore, a genetic double deficiency approach would not be
informative as to the actual role of Factor H. Thus, we set up
an in vitro model of C3 deposition on Ptx3+/+ and Ptx3/ cell
lines, in the presence of recombinant PTX3 and a recombinant
Factor H inhibitor (SRC19-20) (Banda et al., 2013). For these ex-
periments, we selected one wild-type sarcoma line (Wt-2),
generated on day 100, which, unlike most wild-type cell lines
(Figure S2C), produces detectable levels of PTX3 (8 ng/ml in
24 hr). In line with results obtained in vivo (Figure 4B), C3 depo-
sition was significantly higher on Ptx3/ than onPtx3+/+ produc-
ing cells (Figures 4J and 4K). Recombinant PTX3 reduced C3
deposition on Ptx3/ cells abrogating the difference between
Ptx3+/+ and Ptx3/ cells, and SRC19-20 that interferes with
the interaction between PTX3 and Factor H (Deban et al.,
2008), caused higher C3 deposition on Ptx3+/+ cells and did
not further increase C3 deposition on Ptx3/ cells. Notably,
the rescue of C3 deposition on Ptx3/ cells obtained with re-
combinant PTX3 was abolished in the presence of SRC19-20.
To further address whether PTX3 regulates immune com-
plexes (IC)-dependent Complement and leukocyte activation,
we measured circulating IC and analyzed their composition
and proinflammatory activity. PTX3 deficiency was associated
with normal levels of total IC and C3-containing IC (Figure S4C).
Qualitative analysis revealed the presence of PTX3 in IC, but the
amount of C3, C1q, and total Ig did not differ between Ptx3+/+
and Ptx3/ IC (Figure S4D). Finally, Ptx3+/+ and Ptx3/ IC
equally activated macrophages (expression of polarization
markers and cytokines) indicating that PTX3 does not regulate
CRI through IC in this cancer model (Figure S4E).
All together, these data suggest that Complement is an essen-
tial component of tumor-promoting inflammation and that the
increasedComplement activation associated to PTX3 deficiency
due to lack of recruitment of Factor H has a major role in sus-
taining an exacerbated inflammatory response and enhanced
carcinogenesis.
Other Components of Cancer-Related Inflammation
As shown in Figure 3C and Table S1, PTX3 deficiency was asso-
ciated with increased macrophage infiltration and increased
levels of themonocyte attracting chemokine CCL2. Complement
activation and C5a in particular induce chemokine production. It
was therefore important to assess the role of CCL2 in the
increased susceptibility to carcinogenesis exhibited by PTX3-
deficient mice. To this aim, we treated Ptx3/ and Ptx3+/+
mice with an anti-CCL2 Ab. As shown in Figure 5A, the anti-
CCL2 treatment did not modify the tumor incidence of Ptx3+/+
mice, whereas it reduced the susceptibility of Ptx3/ mice,
completely reverting the phenotype.
CCL2 has been shown to skew macrophage polarization in an
M2-like direction (Roca et al., 2009; Sierra-Filardi et al., 2014), we
therefore characterized the phenotype of tumor-associatedmacrophages (TAM) in Ptx3/ and Ptx3+/+ mice. Upon puri-
fication of CD11b+/Ly6G cells, MHCIIhigh (CD11b+/Ly6C/
MHCIIhigh) and MHCIIlow (CD11b+/Ly6C/MHCIIlow) macro-
phages and monocytes (CD11b+/Ly6C+/MHCII) were sorted
to >98% purity to analyze the expression of M1- and M2-like
markers as described (Laoui et al., 2014). As shown in Figures
5B–5D and Table S2, Ptx3/ MHCIIhigh and MHCIIlow macro-
phages and monocytes expressed higher levels of M2-like
markers (in particular Arg1, Ym1, Fizz1, Il10, andMcr1 in macro-
phages and Ym1 and Fizz1 in monocytes) and lower levels of M1
markers (in particular Il12a and Ifng) in comparison to Ptx3+/+
macrophages and monocytes. Moreover Ptx3/ macrophages
(MHCIIhigh or MHCIIlow) expressed higher levels of Nos2, which is
overexpressed by TAMs (Murray et al., 2014).
Increased Trp53 Mutations and DNA Damage in
Ptx3/ Mice
Because CRI is potentially a cause of gene instability (Colotta
et al., 2009), we next addressedwhether the increased tumor inci-
dence observed in Ptx3/ mice was associated to increased
gene mutation. To this aim, we evaluated the frequency of muta-
tions in Trp53 and Kras, which are target genes mutated by 3-
MCA, in sarcoma cell lines isolated from Ptx3/ and Ptx3+/+ tu-
mor-bearingmice. The genomic DNAof 10Ptx3+/+ and 12Ptx3/
3-MCA-induced sarcomaswas examined by direct sequencing of
exons 5 to 8 of the Trp53 gene and of exons 1 and 2 of Kras gene.
In line with previous studies (Watanabe et al., 1999), eight out of
ten wild-type sarcomas (80%) carried mutations of Trp53 gene
in 12 different codons, whereasKrasmutations were less frequent
(20%) and were restricted to two codons (Table S3). As shown in
Figure 6A, the number of Trp53mutations was significantly higher
in Ptx3/ than in Ptx3+/+ sarcoma cell lines, whereas no differ-
enceswere observed inKras genemutations (Figure 6B). Interest-
ingly, similar numbers of mutations were observed in Ptx3/ cell
lines collected 100 days upon treatment or at the end point (tumor
volume 3 cm3) suggesting that the increased Trp53 gene in-
stability is not due to accumulation of mutations during tumor
progression (Table S3).Wefinally addressed the functional conse-
quences of Trp53 mutations. As shown in Figure 6C, the expres-
sion ofMdm2,Bax, andCdkn1a (p21) downstreamp53 activation,
was significantly reduced inPtx3/ tumor cell lines in comparison
to Ptx3+/+, indicating that the higher incidence of Trp53mutations
observed in Ptx3/ is likely associated with increased loss of
onco-suppressor function.
To further investigate whether and to what extent the
increased inflammation in Ptx3/ mice translated into DNA
damage we studied DNA damage by performing immunohisto-
chemical analysis of 8-OH-deoxiguanosine (8-OH-dG), a modi-
fied DNA base generated during oxidative damage. As shown
in Figure 6D, the number of 8-OH-dG-positive nuclei was signif-
icantly higher in Ptx3/ than in Ptx3+/+ tissues 15 days after 3-
MCA injection. In addition, the expression of the DDR markers,
g-H2Ax and 53BP1 was significantly higher in Ptx3/ tissues
(Figures 6E and 6F). The relevance of damage caused by reac-
tive species was addressed by treating 3-MCA-injected mice
with amminiguanidine hemisulphate (AG), an irreversible inhibi-
tor of iNOS. AG significantly reduced the tumor incidence in
Ptx3/ mice (Figure 6G). In addition, treatment with AGCell 160, 700–714, February 12, 2015 ª2015 Elsevier Inc. 705
Figure 4. PTX3 Deficiency Is Associated to Increased Complement Deposition in 3-MCA-Sarcoma
(A–C) Analysis by confocal microscopy of C3 deposition in the injection site (*) at 7 days (A) or in tumors (B and C) of Ptx3/ and Ptx3+/+ mice, after treatment with
recombinant PTX3 (from day 0 to 100) (C). Correlation analysis between C3 and PTX3 expression was performed in wild-type tumors (B).
(D) Analysis by ELISA of C5a concentrations, (mean ± SEM, two pooled experiments), in 3-MCA-tumors.
(E and F) Analysis by confocal microscopy of C5b-9 (E) and Factor H (F) in 3-MCA-tumors. Correlation analysis between Factor H and PTX3 expression was
performed in wild-type tumors.
(G) Incidence of 3-MCA-sarcoma in C3/ and/or Ptx3/ and Ptx3+/+ mice (n = 10–15).
(H) Analysis of the macrophage (F4/80+/CD11b+) infiltrate in 3-MCA-sarcoma by FACS in C3/ and/or Ptx3/ and Ptx3+/+ mice.
(I) 3-MCA-sarcoma incidence in Ptx3/ and Ptx3+/+ mice treated with the C5aR antagonist PMX53 (n = 7).
(legend continued on next page)
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Figure 5. Role of CCL2 in Carcinogenesis and TAM Polarization in PTX3-Deficient Mice
(A) Incidence of 3-MCA-sarcoma in Ptx3/ and Ptx3+/+ mice treated with anti-CCL2, or irrelevant mAb (n = 9–11) (100 mg/mouse three times/week) for the
duration of the experiment. ***p < 0.001, paired Student’s t test.
(B–D) Analysis by RT-PCR of selectedM1 andM2markers of macrophages (B and C) andmonocytes (D) infiltrating 3-MCA-sarcoma in Ptx3/ and Ptx3+/+ mice
(mean ± SEM). *p < 0.05, **p < 0.01, ***p < 0.001, unpaired Student’s t test. In (B), (C), and (D), data were relative to 18S expression and normalized versus the
mean of wild-type and expressed as mean ± SEM.
See also Table S2.abolished the difference in 8-OH-dG and g-H2Ax immunoreac-
tivity between Ptx3/ and Ptx3+/+ tissues (Figures 6D and 6E).
These results suggest that increased CRI in PTX3-deficient
mice is associated with increased genetic instability as assessed
by the frequency of Trp53 mutations, oxidative DNA damage,
and expression of DDR markers.
Methylation of the PTX3 Gene in Human Cancer
We next investigated whether results obtained in the mouse are
indeed relevant to human cancer. Studies in human esophageal(J) Immunofluorescence analysis of C3 deposition on Ptx3+/+ and Ptx3/ cells, i
indicate faint C3 immunostaining in Ptx3+/+ cells in basal conditions or after add
(K) Quantification of C3 deposition evaluated by immunofluorescence. *p < 0.0
Student’s t test (G and I). For (A), (B), (C), (E), (F), and (K), each dot represents the a
(A–C, E, and F) or well (K) (mean ± SEM). Scale bars represent 150 mm.
See also Figure S4.squamous cell carcinoma had shown that the PTX3 promoter is
hypermethylated in this cancer and PTX3 expression is inhibited
(Wang et al., 2011). In addition, in silico bioinformatics analysis
in the Epigenomics database (http://www.ncbi.nlm.nih.gov/
epigenomics) showed PTX3 gene methylation in colorectal can-
cer (CRC) (File: GSM801957). We thus analyzed the methylation
status of the promoter and of a CpG island located in a putative
enhancer encompassing the second exon (Akhtar-Zaidi et al.,
2012) in a series of mesenchymal and epithelial cancers. As
shown in Figure 7A, both the promoter and the CpG island aren the presence of recombinant PTX3, SRC19-20, or their combination. Arrows
ition of PTX3 in the assay.
5, **p < 0.01, ***p < 0.001, unpaired Student’s t test (A–F, H, and K), paired
verage of mean fluorescence intensity of ten regions of interest (ROI) per tumor
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Figure 6. PTX3 Deficiency Is Associated to Increased Genetic Instability
(A and B) Number of Trp53 (A) and Kras (B) mutations (mean ± SEM) in cell lines isolated from Ptx3/ and Ptx3+/+ tumors. See also Table S3.
(C) Analysis of the expression of p53-regulated genes by RT-PCR in cell lines isolated from Ptx3/ and Ptx3+/+ tumors. Data were relative to GAPDH expression
and represented as mean ± SEM.
(D) Immunohistochemical analysis of 8-OH-dG 15 days after 3-MCA injection inPtx3+/+ andPtx3/mice treatedwith AG. Left: data are reported asmean number
± SEM of 8-OH-dG+ nuclei per field. Right: representative immunofluorescence images are shown.
(E and F) Immunofluorescence analysis of g-H2Ax (E) and 53BP1 (F) 15 days after 3-MCA injection in Ptx3+/+ and Ptx3/ mice treated with AG (E). Left panels:
data are reported as MFI of g-H2Ax (E) and 53BP1 (F) positive foci per field and expressed as (mean ± SEM). Right panels: representative immunofluorescence
images are shown.
(G) Sarcoma incidence inPtx3+/+ andPtx3/mice treatedwith AG in the drinkingwater for the entire duration of the experiment. *p < 0.05, **p < 0.01, ***p < 0.001,
unpaired (A-F) or paired (G) Student’s t test.highly methylated in leyomiosarcomas, desmoid tumors, CRC,
and skin squamous cell carcinoma, in contrast with normal
mesenchymal or epithelial tissues. We further investigated
PTX3 methylation and the functional consequences in CRC.708 Cell 160, 700–714, February 12, 2015 ª2015 Elsevier Inc.We analyzed PTX3 methylation in five patients with high-grade
adenomas and 40 patients with microsatellite stable CRC at
different stage (I–IV). As shown in Figure 7B, the methylation of
the promoter region and of the CpG island progressively
increased from normal colon epithelium, to adenomas and to
CRC independently of stage. The healthy tissue from CRC
patients was more methylated than normal colon epithelium.
Similar results were obtained in colorectal tumor cell lines (Fig-
ures 7C and S5A), in which treatment with the methylation inhib-
itor 5-Aza-20-deoxycytidine (5-AZA-dC) significantly reduced the
methylation of both the promoter and theCpG island. In the pres-
ence of 5-AZA-dC, the expression of PTX3 mRNA was signifi-
cantly increased in five different cell lines analyzed, both under
basal conditions and upon stimulation with TNFa or IL-1b (Fig-
ures 7D and S5B). Rescue of PTX3 protein expression was
confirmed in 3 different cell lines (Figures 7D and S5C). In con-
trast, treatment with 5-AZA-dC did not increase PTX3 expres-
sion in normal endothelial or normal colon epithelial cells stimu-
lated with TNFa (Figures S5D and S5E). In addition, chromatin
immunoprecipitation (ChIP) analysis showed that histone modi-
fications associated to transcriptional activation (H3K4me3,
H3K27ac, and H3K9ac) were strongly increased in the PTX3
promoter after treatment with 5-AZA-dC and TNFa, whereas tri-
methylation of H3K27 associated to gene repression was not
modified (Figure S5F). Finally, the binding of NF-kB, c-Jun, and
c-Fos to their consensus binding sites in the promoter and tran-
scription factor binding sites where above the basal level only
after cell treatment with 5-AZA-dC in association with a proin-
flammatory stimulus in CRC cells (Figure 7E). Collectively, these
data suggest that the PTX3 gene is silenced by methylation in
selected human tumors including CRC.
DISCUSSION
The general objective of this investigation was to gain insight into
the role of the humoral arm of innate immunity in CRI using the
long pentraxin PTX3 as a paradigm (Bottazzi et al., 2010). We
observed increased susceptibility to mesenchymal (3-MCA)
and epithelial (DMBA/TPA) carcinogenesis in PTX3-deficient
mice. The 3-MCA model was used for further analysis. This
phenotype was associated with increased macrophage infiltra-
tion, cytokine production, angiogenesis, and genetic instability
as revealed by an increased frequency of Trp53 mutations,
oxidative DNA damage, and expression of DDR markers in
Ptx3/ mice. Several lines of evidence suggest that PTX3 defi-
ciency unleashes unrestrained Complement activation with pro-
duction of C5a, CCL2 production, and enhanced recruitment of
tumor-promoting macrophages. In selected human tumors (e.g.,
leiomyosarcomas and CRC) PTX3 expression was regulated
epigenetically by methylation of the promoter region and of a pu-
tative enhancer. Thus, an essential component of the humoral
arm of innate immunity and regulator of Complement activation
acts as an extrinsic oncosuppressor by acting at the level
of Complement-mediated, macrophage-sustained, tumor-pro-
moting inflammation.
PTX3 is a humoral pattern recognition molecule essential
for resistance against selected microorganisms including
A. fumigatus, P. aeruginosa (Garlanda et al., 2002), Klebsiella
pneumonia (Soares et al., 2006), and uropathogenic Escherichia
coli (Jaillon et al., 2014). PTX3 is highly conserved in evolution
and genetic evidence is consistent with a role of PTX3 in antimi-
crobial resistance in humans (Chiarini et al., 2010; Cunha et al.,2014; Olesen et al., 2007). PTX3 has antibody-like properties,
including recognition of microbial moieties (Jeannin et al.,
2005), opsonization via Fcg receptors (Moalli et al., 2010), Com-
plement activation and regulation (Deban et al., 2008; Inforzato
et al., 2013), and regulation of inflammation (Deban et al., 2010;
Lech et al., 2013; Norata et al., 2009; Salio et al., 2008; Soares
et al., 2006). Given the fact that tumor-promoting inflammation
is now recognized as an essential component of the tumormicro-
environment (Coussens et al., 2013; Grivennikov et al., 2010; Ha-
nahan and Weinberg, 2011; Mantovani et al., 2008), the
increased susceptibility of PTX3-deficient mice to carcinogen-
esis is a reflection of its regulatory function on inflammation.
PTX3 binds P-selectin via its glycosidic component (Deban
et al., 2010) and this accounts for the regulatory function on
inflammation of PTX3 in selected P-selectin-dependent experi-
mental models (Lech et al., 2013). It was therefore important to
assess the relevance of the P-selectin pathway in the enhanced
carcinogenesis observed in Ptx3/ mice. P-selectin-deficient
mice show no phenotype in terms of 3-MCA carcinogenesis.
Moreover, PTX3/P-selectin-double-deficient mice showed
enhanced 3-MCA carcinogenesis compared to controls. Thus,
the P-selectin pathway is not involved in the enhanced suscep-
tibility to carcinogenesis of PTX3-deficient mice.
PTX3 interacts with Complement at multiple levels (Inforzato
et al., 2013). It binds C1q (Bottazzi et al., 1997) and activates
or regulates (Nauta et al., 2003) the classic pathway of Comple-
ment activation. By interacting with ficolins and MBL it indepen-
dently impinges upon the alternative pathway (Gout et al., 2011;
Ma et al., 2009). PTX3 interacts and recruits Factor H by binding
domains 19–20 and 7 through its N-terminal and glycosylated
C-terminal domains, respectively, without interfering with Factor
H capacity to negatively regulate the Complement cascade (De-
ban et al., 2008). We found an inverse relationship between C3
deposition and PTX3 presence in individual tumors. Conversely,
the occurrence of Factor H was directly and significantly corre-
lated with PTX3 deposition. In an effort to assess the actual sig-
nificance of the Complement cascade in the onco-suppressive
function of PTX3, double C3/PTX3-deficient mice were gener-
ated. Genetic inactivation of C3 strongly reduced, but did not
completely ablate, the tumor-promoting function of PTX3 defi-
ciency, suggesting that other mechanisms in addition to un-
leashed complement may contribute to increased CRI and sus-
ceptibility to cancer in PTX3-deficient mice.
A genetic approach to address the role of Factor H in vivo us-
ing double knockout mice is hindered by systemic C3 consump-
tion and associated pathology in Factor H-deficient mice (Banda
et al., 2013; Pickering et al., 2002). However, in an in vitro assay
of C3 deposition on PTX3 competent and PTX3-incompetent cell
lines, a recombinant Factor H inhibitor (SRC19-20) (Banda et al.,
2013), which interferes with the binding between PTX3 and Fac-
tor H (Deban et al., 2008), increased C3 deposition on PTX3 pro-
ducing cells and abolished the rescue of C3 deposition on
Ptx3/ cells obtained with recombinant PTX3. Thus, we infer
that PTX3 deficiency unleashes Complement-dependent, C5a-
mediated tumor-promoting inflammation, because of defective
recruitment of the negative regulator Factor H.
Complement is not considered a canonical component of tu-
mor-promoting inflammation (Coussens et al., 2013; HanahanCell 160, 700–714, February 12, 2015 ª2015 Elsevier Inc. 709
Figure 7. The PTX3 Gene Is Epigenetically Modified in Human Cancers
(A) Analysis by methylated CpG island recovery assay (MIRA) of the percentage of methylation enrichment of the promoter region and of the PTX3 CpG island in
human mesenchymal and epithelial tumors. CpG rich regions (iCGs) (P1, P2, transcription factor binding site [TFBS], and CpG island [iCG1-9]) and surrounding
(legend continued on next page)
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and Weinberg, 2011; Mantovani et al., 2008). Complement can
represent an effector mechanism against hematopoietic tumors
activated bymonoclonal antibodies (Golay et al., 2001). The gen-
eration of Complement C5a in a transplanted tumor enhanced
growth by recruiting myeloid-derived suppressor cells and
amplifying their T cell-directed suppressive abilities (Markiewski
et al., 2008). However, no information based on genetic ap-
proaches concerning the role of Complement components in
carcinogenesis is available. Here, we found that C3-deficient
mice are strongly protected against 3-MCA (Figure 4G) and
DMBA/TPA (Figure S4B) carcinogenesis, involving mesen-
chymal and epithelial cells, respectively. These results demon-
strate that Complement is an essential component of tumor-pro-
moting inflammation.
The Complement cascade can be activated by antibodies or
by sensing tissue damage (Ricklin et al., 2010). Antibodies
have been shown to orchestrate cancer-related inflammation
in a model of epithelial carcinogenesis (HPV16 transgenic
mice) by a remote control mechanism (Andreu et al., 2010).
However, in that system the pathway driving tumor-promoting
inflammation was Fcg receptor-dependent and Complement-in-
dependent (Andreu et al., 2010; de Visser et al., 2004). It is
therefore tempting to speculate that an antibody-independent
pathway (e.g., interaction with senescent or apoptotic cells) is
responsible for Complement-mediated orchestration of tumor-
promoting inflammation in the two models of mesenchymal
(3-MCA) and epithelial (DMBA/TPA) carcinogenesis used in the
present study. Interestingly, in the present study, C3-deficient
mice showed reduced susceptibility to DMBA/TPA skin carcino-
genesis but were not protected against HPV16-driven squamous
carcinoma development (Andreu et al., 2010; de Visser et al.,
2004). CRI can differ considerably in its drivers and components
in tumors originating in different organs and tumors (Ruffell et al.,
2012). It is likely that Complement may play different roles in
different carcinogenesis contexts.
Macrophages are an essential component of tumor-promot-
ing inflammation (Qian and Pollard, 2010; Sica and Mantovani,
2012). Tumors originating in a PTX3-deficient context were char-
acterized by an increased frequency of TAM throughout the nat-
ural history of the tumor. Increased macrophage accumulation
was completely abolished in C3-deficient or C3/PTX3-double-
deficient hosts. PTX3 deficiency was associated with increased
C5a and CCL2. Both molecules are potent monocyte attrac-
tants. Interestingly at the end point (tumor volume 3 cm3) macro-
phage, but not neutrophil, numberswere increased in PTX3-defi-regions analyzed by MIRA are shown below the structure of PTX3 gene. Healthy
(n = 3) and skin squamous carcinoma (n = 5); healthy mesenchymal tissues wer
desmoid tumor (n = 2) patients.
(B) Analysis by MIRA of the percentage of methylation enrichment of the same
counterparts for each CRC stage.
(C) Analysis by MIRA of the percentage of methylation enrichment of the same re
(RKO and HCT116) treated or not with the inhibitor of DNA methylation 5-AZA-d
(D) PTX3mRNA expression and protein production by RKO and HCT116 cell lines
mL. Healthy colon: primary human intestinal epithelial crypt cells isolated from s
(E) Analysis by ChIP of NF-kB, c-Fos, and c-Jun binding to the promoter, TFBS
presence of TNFa 20 ng/ml. Data are expressed as percentage of enrichment rela
SEM. *p < 0.05, **p < 0.01, ***p < 0.001, unpaired Student’s t test.
See also Figure S5.cient hosts, consistent with a function of CCL2 in sustaining TAM
recruitment and tumor-promoting inflammation. Macrophages
in tumors usually acquire a skewed M2-like phenotype oriented
to tumor promotion (Sica and Mantovani, 2012). Chemoattrac-
tants, and CCL2 in particular, have been shown to skew macro-
phage function in an M2-like direction (Roca et al., 2009). In
PTX3-deficient hosts, TAM showed enhanced expression of
molecules associated with M2-like polarization, including Arg I,
Fizz1, and Ym1. Skewing of macrophage function with, for
instance, increased immunosuppressive activity and may
contribute to enhanced carcinogenesis in PTX3-deficient hosts.
Antibodies directed against CCL2 reverted the phenotype of
PTX3-deficient mice in terms of enhanced susceptibility to 3-
MCA carcinogenesis but did not protect PTX3-competent
mice, as observed in other murine models and clinical trials (Lo-
berg et al., 2007; Pienta et al., 2013) suggesting that the treat-
ment is effective only under conditions of exacerbated CCL2
production and M2-polarization. Chemoattractants including
C5a induce chemokines (Sozzani et al., 1995). Thus, uncon-
trolled Complement activation with C5a production is likely to
be upstream of CCL2 that in turn recruits tumor-promoting
TAM in increased numbers, with skewed M2-like phenotype, in
PTX3-deficient hosts. However, the strong reduction of TAM in
PTX3/C3-double-deficient mice was not sufficient to completely
rescue the susceptibility to carcinogenesis of Ptx3/mice, sug-
gesting the involvement of other cell types or mechanisms in
addition to increased TAM in the observed phenotype.
Inflammatory mediators have been suggested to contribute to
genetic events that cause cancer and to the genetic instability of
tumors, although there is little formal evidence for that (Colotta
et al., 2009). PTX3 is an extracellular molecule whose only
cellular receptors identified so far are Fcg receptors (Lu et al.,
2008; Moalli et al., 2010). PTX3 does not affect the growth and
death of normal or neoplastic cells. PTX3-deficient mice showed
increased susceptibility to carcinogenesis mediated by Comple-
ment-dependent tumor-promoting inflammation. Tumors devel-
oped in a PTX3-deficient context characterized by exacerbated
inflammation had a higher frequency of Trp53 mutations, in-
creased DNA oxidative damage and higher expression of DDR
markers (Figure 6). These findings indicate that exacerbated
inflammation in the tumor microenvironment can indeed
contribute to the genetic instability of cancer.
In an effort to assess the actual significance of the present
findings to human cancer, supported by a bioinformatics anal-
ysis showing methylation of the PTX3 gene in CRC, we searchedepithelial tissues were from the normal counterpart of colon cancer patients
e from leiomyosarcoma (n = 1), angiosarcoma (n = 3), chordoma (n = 3), and
regions in healthy colon epithelium, high grade adenomas, CRC, and healthy
gions in one normal colon epithelial cell line (HcoEpic) and two CRC cell lines
C.
treated or not with 5-AZA-dC in the presence of TNFa 20 ng/mL or IL-1b 20 ng/
urgical biopsies.
, and an irrelevant region in RKO cell line treated or not with 5-AZA-dC in the
tively to input DNA normalized on a positive control and represented as mean ±
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for epigenetic modifications of the PTX3 gene in mesenchymal
and epithelial tumors. In selected human tumors (e.g., leiomyo-
sarcomas, CRC, and skin squamous cell carcinoma), we found
that the PTX3 gene was hypermethylated at the promoter region
and in a CpG rich putative enhancer encompassing exon 2. The
latter is indeed a functional enhancer (M.R., unpublished data).
PTX3 gene methylation was detected in CRC stages 1–4 as
well as in adenomas, suggesting that this is an early event in
the natural history of CRC (Vogelstein et al., 2013). Hypermethy-
lation at the PTX3 locus was also observed in CRC cell lines,
where treatment with 5-AZA-dC rescued the PTX3 production
in response to inflammatory cytokines. ChIP analysis showed
that only after treatment with 5-AZA-dC and an inflammatory
stimulus of CRC cells, histone modifications associated to tran-
scriptional activation occurred and the transcription factors
responsible of PTX3 expression (e.g., NF-kB, c-Jun, c-Fos) inter-
acted with their binding sites in the PTX3 promoter region. Thus
the PTX3 gene is silenced by hypermethylation in selected hu-
man tumors including CRC and this event occurs early in pro-
gression already at the level of adenomas.
The results presented here demonstrate that a regulatory
component of the humoral arm of innate immunity, PTX3, acts
as an extrinsic oncosuppressor gene in mouse and man.
Although the connection between inflammation and cancer has
long been perceived (Coussens et al., 2013; Grivennikov et al.,
2010; Hanahan and Weinberg, 2011; Mantovani et al., 2008),
we are not aware of a precedent for a humoral innate immunity
effector molecule acting as a cancer gene. An additional general
implication of the results reported here relates to Complement.
The results obtained suggest that Complement is a key compo-
nent of tumor-promoting cancer-related inflammation.
EXPERIMENTAL PROCEDURES
Cancer Models
Mice were injected s.c. with a single dose of 100 mg of 3-MCA (Sigma-Aldrich)
dissolved in corn oil and assessed for tumor development over the course of
5 months. Skin carcinogenesis was performed as reported (Schioppa et al.,
2011) in a two-step DMBA/TPA model. Procedures conformed to protocols
approved by the Humanitas Clinical and Research Center in compliance
with national and international law and policies. The study was approved by
the Italian Ministry of Health.
Analysis of Complement Deposition
Deposition of Complement components was analyzed by confocal micro-
scopy on tumor tissue or cell lines. C3 deposition on tumor cell lines was
performed by incubating cells with 10% normal mouse serum in gelatin-con-
taining Veronal buffer, recombinant PTX3, and/or 33 nMFactor H inhibitor pep-
tide SRC19-20 (Braunschweig and Jo´zsi, 2011).
Analysis of DNA Damage
Genomic DNA was extracted from 10 Ptx3+/+ and 12 Ptx3/ 3-MCA-induced
sarcoma cell lines, and the direct sequencing of exons 5 to 8 of Trp53 gene
and of exons 1 and 2 of Kras gene was performed as previously reported
(Watanabe et al., 1999). DNA damage marker (8-OH-dG) and DDR markers
(g-H2Ax and 53BP1) were analyzed by immunohistochemistry and
immunofluorescence.
Patients
Paraffin-embedded tissues from oncologic Caucasian patients, who under-
went resection surgery at Humanitas Clinical and Research Center, were
examined for PTX3 gene epigeneticmodification bymethylated CpG island re-712 Cell 160, 700–714, February 12, 2015 ª2015 Elsevier Inc.covery assay (MIRA). The Institutional Review Board of the Humanitas Clinical
and Research Center approved this study (ICH-99/09).
Detailed procedures for in vivo studies, biochemical assays, FACS analysis,
immunostaining and confocal analysis, quantitative PCR, statistical analysis,
and all other methods are described in Extended Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, five
figures, and three tables and can be found with this article online at http://
dx.doi.org/10.1016/j.cell.2015.01.004.
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